1 MARKET UPDATE
One of the few medical device companies globally with the leading edge technology to participate in the remote
monitoring of chronic disease symptoms.
Respiri is a software company with decades of experience in researching and developing clinical products for
hospitals. Respiri has the world’s first digital wheeze detection technology for the management of asthma. Smart
proprietary machine learning algorithms detect and measure wheeze, the major symptom of asthma.
New, leading edge technology has recently been employed in its consumer product, the AirSonea® Wheeze
Monitor, an over the counter remote monitoring product that is not reliant on doctor prescriptions. Respiri has a
large global target market of parents and carers of children who cannot use lung function tests.
Health conscious consumers are rapidly embracing patient self-management and remote monitoring with
smartphones that provide the growth engine for the company’s AirSonea product.
2
RESPIRI LIMITED
Outstanding progress in delivering an asthma monitoring and management business model that uses acoustic
sensors, leading edge machine learning algorithms and software platforms to deliver an over the counter
consumer product without the need for GP prescriptions.
1. Established a clear product position in a major asthma segment with no current competitor.
2. Targets a major unmet consumer need with its primary market, parents and carers of children.
3. Delivers outstanding technology with its leading edge software platform and smart sensors.
4. Commenced ground breaking research and product development for the overnight monitoring of asthma
symptoms.
5. Undertaking exciting partnership discussions for global and regional markets with a primary focus on UK and
Asia.
3
Current company valuations do not reflect Respiri's unique competitive position in a major global
asthma segment and the strength of its leading edge mHealth software platforms.
There is compelling evidence for asthma self-management and respected industry leaders in the
UK, China and the USA now recognise that mHealth solutions can transform asthma care.
RESPIRI STRATEGY & INVESTMENT ATTRIBUTES
4
RESPIRI CORPORATE SNAPSHOT
CAPITAL STRUCTURE
ASX code RSH
Shares on issue 432mil
Unlisted options
(various ex. prices)15.1mil
Share price6.0
cents
Market capitalisation $25.9mil
BOARD OF DIRECTORS
Leon L’HuillierExecutive
Chairman
Tim OldhamNon-Executive
Director
John Ribot-de-
BresacNon-Executive
Director
SHARE REGISTER
Top 20 shareholders 37.95%
Substantial
shareholders:
Investment Holdings
Pty Ltd
17.05%
Total number of
shareholders
(30 August 2016)
4,315
5
WHEEZE IS THE MAJOR SYMPTOM OF ASTHMA
Normal
Bronchiole
Airway
Muscle layer
Mucus gland
Inflamation & mucus
Muscle contracts
Airway opening is
reduced
Asthma
Airflow Limitation The main symptoms of asthma:
Wheezing
Shortness of breath
A tight chest
Coughing
When airways become inflamed, flow
pressure changes during respiration causing
the airway wall to flutter. This flutter results
in acoustic energy, or wheeze. The flutter or
wheeze is a manifestation of airway flow
limitation.
“... People with asthma typically experience
wheezing.”
“... If an infant presents with frequent and/or
severe episodes of recurrent wheezing they
should be diagnosed and managed as asthma,
unless there is evidence to the contrary.”
Global Asthma Report 2014
Over 340 million people globally suffer from asthma, rising to 400 million by 2025
• Asthma still kills and 2/3 of asthma deaths are preventable
• Poor asthma management is a major problem and an economic burden on society
Respiri is focused on one clear segment of the asthma market: objective measurement of wheeze
in diagnosed asthmatics with a convenient and easy to use consumer product.
Diagnosis
Difficult. No ‘single reliable gold
standard test’.
Spirometry devices to measure airflow
and limitation are the universally
accepted device by physicians.
Multiple manufacturers
Monitoring & Management
Assessing symptom control and risk,
using paper asthma plans.
Outdated peak flow meters the only
competitor and do not work for
consumers due to poor technique and
inaccurate recording.
Respiri’s AirSonea®
Medication compliance
Smart inhaler devices connected to
smart phones to measure and track
medication compliance.
Propeller Health, 3M, Adherium
6
CLEAR PRODUCT POSITION IN ASTHMA SYMPTOM MONITORING & MANAGEMENT
WITH NO CURRENT COMPETITOR
Primary target market: Parents and carers of children. Secondary target market older people.
Latest independent consumer market research (November 2016)
Parents: “crying out” for greater support and understanding to proactively manage a child's asthma.
• Greater understanding of child’s condition and ability to detect any early signs of change. Often cannot
remember all the asthma sign/trigger details leading up to an asthma episode – they are stressed, living busy
lives.
• Would like asthma period/historical data and trends that they are able to discuss with GP to enhance
management.
• Want a tool that they can send with their child to grandparents, on sleepovers and on holidays to monitor their
child’s asthma status. Confirms previous consumer research by Proctor & Gamble/Tremor and EY Sweeney.
Healthcare Professionals:
• Over three-quarters of healthcare professionals in the UK said they would value a mHealth system that would
monitor patients’ asthma symptoms between visits and provide patients with an asthma action plan.
Asthma Associations:
• Mark Brooke, Asthma Australia. “Poorly managed asthma has tragic consequences and better treatment plans
are needed”.
• Kay Boycott, Asthma UK. “The majority of the people in the UK would welcome a mHealth solution to help them
manage their long term condition”.
7
TARGETS A MAJOR UNMET CONSUMER NEED WITH ITS PRIMARY MARKET,
PARENTS & CARERS OF CHILDREN
AirSonea® utilises a PPG sensor to capture breath sounds at the
trachea. The optimal position for the recording of wheeze is over
the trachea (children, adults & small children). Professor Noam
Gavriely.
The sounds are transmitted to the smartphone application by
Bluetooth and in near real time, the proprietary wheeze
detection algorithm processes the sonogram calculation and
performs the acoustic analysis to deliver a WheezeRATE, an
estimation of the total time of wheeze events as a ratio from the
entire signal. For example, if 15 seconds out of a 30 second
record contained wheeze, the Wz% is 15/30 = 50%.
Respiri’s software solution includes breath detection and
ambient noise rejection.
Medical devices with sensors and connected smartphone
applications are universally used by world leaders for chronic
disease management:
– Dexcom – Diabetes
– Propeller Health – Asthma medication compliance
– Omron & Philips – Blood pressure & ECG
8
DELIVERS OUTSTANDING TECHNOLOGY WITH ITS LEADING EDGE
SOFTWARE PLATFORM & SMART SENSORS
AirSonea app is a digital asthma diary providing
vital monitoring features.
Our proprietary software correlates WheezeRATE
measurements with other asthma symptoms and
triggers, and inhaler use. This helps the patient
understand what triggers are causing their
symptoms and how to avoid possible flare-ups.
The patient has a real time picture of their asthma
in the palm of their hand and doctors have the
complete picture to provide the best possible
individual advice.
The app allows users to set reminders to take
WheezeRATE measurements and preventer
medication to encourage adherence.
AirSonea’s Health Chart clearly shows the correlation between
WheezeRATE, adherence to medication schedule (green dot)
symptoms & triggers (red dot) and the effectiveness of reliever
medication (yellow dot).
This example shows spikes in the WheezeRATE when the preventer
medication has been missed. After the user takes their reliever, the
WheezeRATE drops.
9
A smart digital technology platform for the monitoring and management of asthma
Respiri has accelerated Research & Development expenditure in its 1st half (Q1 $495k)
to have in place a leading edge platform for partner discussions.
DELIVERS OUTSTANDING TECHNOLOGY WITH ITS LEADING EDGE
SOFTWARE PLATFORM & SMART SENSORS
10
• Recently achieved a major milestone with an independently
run research study, conducted by the University of Chicago,
confirming that the AirSonea® technology can reliably detect
wheezing in subjects. The overall percentage agreement
between a panel of certified pulmonary physicians and our
AirSonea technology for the presence or absence of wheeze
was an impressive 85%.
• Long history of previous studies on digital wheeze monitoring
published in prestigious journals by world class physicians and
scientists.
• Multiple studies conducted at major global hospitals including:
Royal Brompton Hospital, London, UK, University of
Edinburgh, Scotland, Charite University Hospital, Berlin,
Germany, University of Chicago, USA, Hadassah University
Hospital, Jerusalem, Israel, Rambam Medical Centre, Haifa,
Israel, Massachusetts General Hospital, USA, California Allergy
and Asthma & UCLA, USA
• 44 patents granted.
LONG HISTORY OF INDEPENDENT SUCCESSFUL CLINICAL STUDIES
Respiri's overnight monitoring research and development, in conjunction with Planet Innovation and
leading academics, will dramatically broaden the company's software technology offering and has
generated strong interest from our industry.
Children's asthma symptoms often worsen overnight, cause great distress to parents and increase healthcare
costs with overnight visits to emergency departments.
Our consumer friendly and objective acoustic technology platform will record the duration of wheezes and
coughs and the number of events over 6-8 hours per night from acoustic sensors.
Respiri's clinical, FDA approved WHolter product provides a solid platform for our new wireless technology
that will provide groundbreaking data and new hardware devices outside of a clinical setting to:
• Parents: alarm alerts and valuable data to discuss with their physicians.
• General practitioners and specialist physicians: can review treatments
• Big pharma: evaluate treatment efficacy of their medications
• Big data companies and healthcare systems: identify key trends
• Baby and child monitoring companies: broader product offerings
11
GROUND BREAKING RESEARCH TO DEVELOP A NEW WIRELESS PRODUCT
FOR OVERNIGHT MONITORING
UK: READY FOR CONNECTED MHEALTH TECHNOLOGY
– Report on “Why asthma still kills” produced a damning assessment of current routine practice in asthma care.
– Almost three quarters of people with asthma in the UK would like to see a mobile health device made available that
would help them monitor their asthma.
– A number of top UK NHS physicians wrote research papers on our wheeze detection algorithms and the benefits.
– Asthma UK, the lead industry body, is enthusiastic about mHealth technology for asthma self management.
– The NHS is a tight distribution channel (GPs , nurses, specialists, clinics, hospitals etc.) in geographical clusters.
ASIA: HIGH POLLUTION CAUSING ASTHMA TO RISE
– Around 2 billion children across the world live in areas with high amounts of air pollution.
– South Asia has the largest number of children living in the polluted areas.
– Dangerous levels are known to increase the risk of asthma and lung cancer.
12
COMMERCIAL IN CONFIDENCE PARTNERSHIP DISCUSSIONS:
INITIAL FOCUS ON UK & ASIA
MULTIPLE LARGE REVENUE STREAMS
• Consumer & Physicians
• Retail pharmacy & electronic retailers
• Telemedicine
• Healthcare systems
• Insurance companies
• Employers
PARTNERSHIP OPPORTUNITIES
• Medical device and disease management
• Telehealth service providers
• Big pharma
• Smartphone apps, Smartwatch, Internet of
Things (IoT)
Our clear, overarching objective is to deliver sales and distribution agreements to gain access to global markets
and collaborative ‘hardware’ partnerships to innovative sensor technology rapidly.
• Sales and distribution agreements are universally accepted by leading companies in medical technology to gain
access to major key global markets.
• Collaborative partnerships with agile and innovative design and manufacturing companies to ensure our sensor
technology (Hardware) has best in class design, components, and low cost manufacture.
Our goal is not to diagnose or replace the physician but to help them keep track of their patients progress in
managing asthma care in the home and between their routine visits to the doctor. And, importantly provide peace
of mind to parents and carers of children.
Exciting progress has been made to date during commercial-in-confidence discussions in several countries. Respiri
is viewed as an innovative, high potential mobile health provider that partners with patients and health care
professionals to transform asthma care.
13
MONETISATION OBJECTIVES IN FY17